The Barbara Ann Karmanos Cancer Institute has released an updated version of the KCI Clinical Trials App on both the Apple App Store and the Google Play Store.
The Barbara Ann Karmanos Cancer Institute has become the first and only independent cancer center in the U.S. to provide a new hemophilia treatment. Etranacogene dezaparvovec-drlb, also known by its brand name Hemegenix, is a one-time gene therapy approved by FDA for the treatment of adults with hemophilia B.
